

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop C1-22-06
Baltimore, Maryland 21244-1850



MEDICARE PARTS C AND D OVERSIGHT AND ENFORCEMENT GROUP

June 25, 2024

Mr. Andrew Clifton
Chief Executive Officer
Zing Health, Inc.
225 West Washington Street, Suite 450
Chicago, IL 60606

RE: Notice of Retraction of Termination and Intermediate Sanctions (Suspension of Enrollment and Marketing) for Medicare Advantage-Prescription Drug Contract Number: H7330

Dear Mr. Clifton:

On December 27, 2023, the Centers for Medicare & Medicaid Services (CMS) notified you of its decision to terminate (effective 11:59:59 P.M. Eastern Standard Time (EST) December 31, 2024) Zing Health, Inc. (Zing Health) Medicare Advantage-Prescription Drug (MA-PD) contract H7330 because contract H7330 failed to maintain a Part D Summary Star Rating of at least three (3) stars for three consecutive years (see §423.509(a)(4)(x)). In addition to the termination, CMS imposed intermediate sanctions on MA-PD contract H7330.

In light of recent court decisions, on June 13, 2024, CMS recalculated the 2024 Star Ratings and contract H7330's Part D Summary Star Rating increased from 2.5 to 3 stars. As a result, Zing Health no longer meets the threshold for a termination or intermediate sanction under 42 C.F.R. §§ 422.510(a)(4)(ix) and 423.509(a)(4)(x). Therefore, CMS is retracting the termination and intermediate sanction for contract H7330.

If you have any questions about this notice, please call or email the enforcement contact provided in your email notification.

Sincerely,

/s/

John A. Scott
Director
Medicare Parts C and D Oversight and Enforcement Group

cc: Kevin Stansbury, CMS/CM/MOEG/DCE
Ashley Hashem, CMS/OPOLE
Adams Solola, CMS/OPOLE
Avalon Gordon, CMS/OPOLE
Seema Darger, HHS/OGC
Matthew Campbell, HHS/OGC
David Hoskins, HHS/OGC